. Author manuscript; available in PMC: 2024 Jan 20.

Published in final edited form as: Nat Rev Methods Primers. 2023 Jul 20;3:55. doi: 10.1038/s43586-023-00247-6

Table 3.

Therapeutic applications of aptamers. Further information can be found in these review articles^{184,227–229}

Modality	Example	Target (Aptamer)	Reference
Aptamer	Antagonist	Nucleolin (AS1411)	²³⁰
Aptamer	Blocking receptor for viral entry into cell	Hemagglutinin (HA12-16)	²³¹
Aptamer-drug conjugates	Targeted delivery of chemotherapeutic agent (Doxorubicin)	Prostate specific membrane antigen (A10)	²³²
Aptamer-radioligand conjugates	Targeted delivery of radiotherapeutic agents for imaging	Tenascin-C (TTA1-^99mTc)	²³³
Aptamer-RNAi	Targeted delivery of short interfering RNA	Prostate specific membrane antigen for knockdown of Lamin A (A9)	²³⁴
Aptamer-RNAi	Targeted delivery of microRNA	Tyrosine kinase Axl for knock-in of tumor suppressor gene (GL21.T-let7g)	²³⁵
Aptamer functionalised nanoparticles	Targeted delivery of liposomes	CEM-CCRF cells (Sgc8)	¹⁸³
Aptamer functionalised nanoparticles	Targeted delivery of gold nanoparticles	Prostate specific membrane antigen (A9)	²³⁶